The cluster is dominated by passive rebalancing, not active conviction. Monitor next 13F filing for active fund entries or exits. The 95% analyst bullish consensus and $3.9B market cap suggest the stock is well-covered but this filing provides no new catalyst signal.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $68.47entry
- T+1 · 5mo ago +2.07%α +1.53% · $69.89
- T+5 · 5mo ago +3.52%α +3.09% · $70.88
- T+20 · 4mo ago +28.92%α +27.03% · $88.27
- T+60 · 2mo ago +35.11%α +30.71% · $92.51
How similar events traded
Executive Summary
Five mega-passive institutional investors (State Street, Fidelity, T. Rowe Price, Schwab, BofA) increased their ORKA holdings by a net $90.1M in Q3 2025, while only Morgan Stanley trimmed a small position. The buying is dominated by passive/index fund managers, suggesting index rebalancing or passive inflows rather than an active investment thesis. The cluster is directionally bullish but lacks conviction from active managers.
Key Financial Metrics
Institutional Positions
Net institutional flow: $90.1M
▲ Buyers (5)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| State Street | ADD | +74.9% | $12.5M | $8.4M |
| Fidelity | ADD | +29.2% | $139.6M | $76.6M |
| T. Rowe Price | ADD | +52.6% | $12.0K | $7.0K |
| Schwab | DOUBLED | +194% | $4.7M | $3.8M |
| BofA | DOUBLED | +319.1% | $1.5M | $1.3M |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | TRIM | -35.3% | $2.3M | $257.0K |
Key Facts
- 5 buyers added $90.1M net; 1 seller trimmed $257K
- All 5 buyers are mega-passive managers (State Street, Fidelity, T. Rowe Price, Schwab, BofA)
- Fidelity alone added $76.6M, representing 85% of total buying
- Morgan Stanley trimmed 35.3% of its position but its value rose $257K due to stock appreciation
- No active hedge funds, activists, or family offices participated in the cluster
Financial Impact
Net institutional buying of $90.1M, with Fidelity contributing $76.6M of that total. Total buyer holdings now $158.4M.
Risk Factors
- Passive buying may reverse if ORKA is removed from an index or if passive flows rotate out of small/mid-cap pharma
- No active manager participation means no informed catalyst thesis to follow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-ORKA-2025-Q3 |
Track record
40 reports on ORKA
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers